Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression

Pedro C Lara*1,2, Marta Lloret1,2, Bernardino Clavo1,2, Rosa M Apolinario2, Luis Alberto Henríquez-Hernández2,3, Elisa Bordón2, Fausto Fontes2 and Agustín Rey2,4

Address: 1Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Spain, 2Canary Institute for Cancer Research (ICIC), Spain, 3Clinic Sciences Department of Las Palmas de Gran Canaria University (ULPGC), Spain and 4Pathology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Spain

Email: Pedro C Lara* - plara@dcc.ulpgc.es; Marta Lloret - mllosae@hotmail.com; Bernardino Clavo - bclavar@gobiernodecanarias.org; Rosa M Apolinario - rapohid@gobiernodecanarias.org; Luis Alberto Henríquez-Hernández - lhenriquez@dcc.ulpgc.es; Elisa Bordón - elisarbr@gmail.com; Fausto Fontes - faustofontes@gmail.com; Agustín Rey - areylop@gobiernodecanarias.org

* Corresponding author

Abstract
Oxygen molecule modulates tumour response to radiotherapy. Higher radiation doses are required under hypoxic conditions to induce cell death. Hypoxia may inhibit the non-homologous end-joining DNA repair through down regulating Ku70/80 expression. Hypoxia induces drug resistance in clinical tumours, although the mechanism is not clearly elucidated. Vaults are ribonucleoprotein particles with a hollow barrel-like structure composed of three proteins: major vault protein (MVP), vault poly(ADP-ribose) polymerase, and telomerase associated protein-1 and small untranslated RNA. Over-expression of MVP has been associated with chemotherapy resistance. Also, it has been related to poor outcome in patients treated with radiotherapy alone. The aim of the present study was to assess the relation of Major Vault Protein expression and tumor hypoxia in clinical cervical tumors. MVP, p53 and angiogenesis, together with tumor oxygenation, were determined in forty-three consecutive patients suffering from localized cervix carcinoma. High MVP expression was related to severe hypoxia compared to low MVP expressing tumors (p = 0.022). Tumors over-expressing MVP also showed increased angiogenesis (p = 0.003). Besides it, in this study we show for the first time that severe tumor hypoxia is associated with high MVP expression in clinical cervical tumors. Up-regulation of MVP by hypoxia is of critical relevance as chemotherapy is currently a standard treatment for those patients. From our results it could be suggested that hypoxia not only induces increased genetic instability, oncogenic properties and metastatization, but through the correlation observed with MVP expression, another pathway of chemo and radiation resistance could be developed.

Introduction
Growing cancers often acquire an increasing number of genetic alterations. Such genetic changes, including chromosomal translocation, gene amplification, intragenic mutation, and gene silencing, are responsible for the activation of oncogenes and the inactivation of tumour-sup-
pressor genes [1]. How cancer cells acquire genetic instability remains unclear. Exposure of cells to adverse conditions like hypoxia can lead to genome alterations, enhancing the progression potential of tumor cells and resistance to oncological treatments [1]. Hypoxia may lead to conditions that causes increased spontaneous damage to DNA or inhibit DNA repair processes, impair DNA repair and cause tumor progression by altered p53 expression and increased angiogenesis [2,3]. Deregulation of DNA repair pathways can contribute to the phenomenon of hypoxia-induced genetic instability within the tumor [4]. Hypoxia is measured in clinical tumors by several techniques, including the Eppendorf polarographic method [2,5]. In cervical cancer patients, hypoxia is commonly associated to a lesser response to treatment and lower survival rates [6,7]. Hypoxic tumors have a significantly higher probability of relapse and death [7] and they are resistant to chemotherapy [8]. Chemo-resistance would be mediated by up-regulation of Major Vault Protein (MVP) through the Hypoxia-inducible factor 1 (HIF-1) as shown in previously studies performed in vitro [9]. Hypoxia inhibits the non-homologous end joining (NHEJ) DNA repair through down-regulating Ku70/80 expression, combined with increased angiogenesis and altered p53 expression [2]. Cervical tumors over-expressing MVP also showed down-regulation of Ku70/80 and BAX [10]. MVP over-expression has been associated with a suppression of NHEJ repair, and subsequent genomic instability [10]. These mechanisms would be responsible for tumor progression in cervical carcinoma. Moreover, MVP over-expression was associated to reduced long-term local control in patients who achieved clinical complete response to radio-chemotherapy [11]. The aim of the present study was to assess the relation between the expression of the Major Vault Protein and tumor hypoxia in clinical cervical tumors.

Methods
Forty-three consecutive patients suffering from localized cervix carcinoma were prospectively included in this study from July 1997 to September 2001 [2]. Patients were diagnosed and treated by definitive radiation at the Hospital Universitario Materno-Infantil, at the Hospital Universitario Dr. Negrín and at the Hospital Universitario Insular in Las Palmas de Gran Canaria (Spain). Written informed consent was given previously. The study was approved by the Research and Ethics Committee of our institution. The mean age of the patients was 49.48 ± 12.79 years (median 41%, range 0–160). P53 expression showed a mean value of 39.15 ± 27.62% (median 35%, range 0–92%). Tumor hypoxia was also known in all patients. Mean tumor hypoxic fraction <2.5 mmHg (HF 2.5) values were 35.89 ± 26.80 (median 35.20%, range 0–91.30%). MVP expression was independent of clinical and histological variables, except for adenocarcinoma tumors. In fact adenocarcinoma tumors (5 cases) included in the present study over-expressed MVP versus 15 out of 38 squamous cancers (p = 0.011). Besides, high MVP expression was related to severe hypoxia as determined by higher hypoxic fractions HF (2.5) (45.82 ± 28.00%) compared to low MVP expressing tumors (27.26 ± 22.96%) (p = 0.022) (Figure 2a). Tumors over-expressing MVP also showed increased angiogenesis (65.41 ± 38.38) compared to low expressing cases (35.89 ± 22.55) (p = 0.003) (Figure 2b). MVP expression was independent of p53 protein expression.
Discussion

In this study we show for the first time that severe tumor hypoxia is related to high MVP expression in clinical cervical tumors. MVP is ubiquitously expressed and, besides chemotherapy resistance, it has been implicated in the regulation of several cellular processes including transport mechanisms, signal transmissions and immune responses [13]. Previous studies have demonstrated that vaults are up-regulated in different multidrug resistant cancer cell lines [14] and resistance models [15,16]. Increased levels of MVP have been reported in numerous cell lines after selection with a wide panel of cytostatic drugs (e.g. doxorubicin, methotrexate, vincristine or cisplatin) [17]. By contrast, tumour necrosis factor-either applied externally or after gene transduction, led to down-regulation of MVP transcription [18]. There are several publications concerning to the relationship between MVP expression and drug resistance in clinical oncology [19-22]. The role of MVP in clinical outcome after radio-chemotherapy in cervical carcinoma [11] and other cancers [23] has been reported. MVP seems to down-regulate the pro-apoptotic gene BAX through its relation with Ku70/80. Ku70/80 are key genes in the NHEJ repair pathway for radiation-induced DNA double strand breaks. Expression of Ku70/80 has been related to survival in patients treated with x-rays [24,25]. Ku70/80 is a central regulator of apoptosis by interacting with BAX [26] and BCL-2, which in turn has been shown to suppress Ku, thus inhibiting NHEJ repair [27]. In the clinical setting, up-regulation of MVP by hypoxia is of critical relevance because chemotherapy is currently a standard treatment for those patients. In the other hand, hypoxia inhibits the NHEJ DNA repair through down-reg-

Table 1: Characteristics of the patients in the study

| Characteristics       | All patients (n = 43) | MVP low (n = 23) | MVP high (n = 20) | P value |
|-----------------------|----------------------|-----------------|------------------|---------|
| Age                   | 49.48 ± 12.79 (29–81) | 49.47 ± 13.68 (29–81) | 49.50 ± 12.04 (32–72) | 0.325   |
| Stage                 |                      |                 |                  |         |
| I                     | 14                   | 5               | 9                |         |
| II                    | 22                   | 13              | 9                |         |
| III                   | 7                    | 5               | 2                | 0.228   |
| Histology             |                      |                 |                  |         |
| Epidermoid            | 38                   | 23              | 15               |         |
| Adenocarcinoma        | 5                    | 0               | 5                | 0.011   |
| Grade                 |                      |                 |                  |         |
| I                     | 5                    | 3               | 2                |         |
| II                    | 19                   | 10              | 9                |         |
| III                   | 19                   | 10              | 9                | 0.952   |
| p53                   | 39.15 ± 27.62 (0–92) | 37.53 ± 28.04 (0–92) | 41.02 ± 27.74 (0–81) | 0.685   |
| Vascular density      | 49.62 ± 33.98 (0–160) | 35.89 ± 22.55 (0–113) | 65.41 ± 38.38 (12–160) | 0.003   |
| Hypoxic fraction      | 35.89 ± 26.80 (0–91.30) | 27.26 ± 22.96 (0–66.30) | 45.82 ± 28.00 (0–91.30) | 0.022   |
| Median pO₂             | 7.61 ± 8.98 (0–41.90) | 7.84 ± 7.85 (0–24.30) | 7.36 ± 10.34 (0–41.90) | 0.863   |

Mean ± standard deviation and range are included as well as p53, vascular density, hypoxic fraction and median of pO₂.

Figure 1
Representative immunostaining of MVP (a), p53 (b) and micro-vessels (c).
ulating Ku70/80 expression [2]. Preclinical studies about the role of hypoxia in cancer cells showed that reduction of pO2 is a favoring factor to increase chemo-resistance [8,28]. In cancer, hypoxia is an adverse prognostic indicator associated with tumor progression and resistance to therapy [29]. Cellular drug delivery and uptake in hypoxic areas are affected by hypoxia. Some chemotherapeutic drugs require oxygen to generate free radicals that contribute to cytotoxicity. Hypoxia induces cellular adaptations that compromise the effectiveness of chemotherapy. Moreover, the expression of several genes controlling tumor cell survival is regulated by hypoxia (e.g., growth factors governing the formation of new blood vessels and hypoxia-responsive transcription factors modulating the expression of genes). The transcription factor Hypoxia-inducible factor 1 (HIF-1) is one of the principal mediators of homeostasis in human tissues exposed to hypoxia. It is implicated in virtually every process of rapid gene expression in response to low oxygen levels [30]. HIF-1alpha is over-expressed in the majority of common human cancers and their metastases, due to the presence of intratumoral hypoxia and as a result of mutations in genes encoding oncproteins and tumor suppressor genes [31,32]. Whether in clinical tumors this chemo-resistance can be reverted by HIF-1 inhibitors deserves to be studied [9]. Pharmacologic manipulation of HIF-1 levels may provide a novel therapeutic approach to diseases like cancer, especially in combination with anti-angiogenic agents [33] that would further reduce tumour oxygenation. Our previously clinical results showed a close relation of clinical hypoxia to increased angiogenesis and in a lesser extent to p53 oncoprotein alteration [2]. Clinical outcome in patients suffering different types of tumours mainly treated by radiation (i.e., cervical and head & neck cancers) depends, at least in part, of those parameters. An increased genetic instability, oncogenic properties, resistance to treatment and increased ability to metastatization are expected.

From our results it could be suggested that hypoxia not only induces increased genetic instability, oncogenic properties and metastatization, but through the correlation observed with MVP expression, another pathway of chemo-resistance could be developed.

**Abbreviations**

HIF-1: Hypoxia-inducible factor 1; MVD: Mean vascular density; MVP: Major Vault Protein; NHEJ: non-homologous end joining.

**Conflict of interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

PCL has been involved in conception and design of the study as well as in drafting the manuscript, and has given final approval of the version to be published. ML has made the measurements of tumour hypoxia and has treated all patients. BC has made the measurements of tumour hypoxia. RMA has made the angiogenesis studies. LAHH has been involved in the writing of the manuscript and type of packaging likewise in the submission process. EB has made the MVP studies. FF has made the p53 studies. AR has reviewed and overlooked all the immunohistochemistry experiments.
Acknowledgements
This work was subsidised by grants: FIS 1035/98, 0855/01. Henriquez-Hernández LA, Bordón E and Fontes F were supported by an educational grant from the Instituto Canario de Investigación del Cáncer (ICIC).

References
1. Huang LE, Bindra RS, Glazer PM, Harris AL: Hypoxia-induced genetic instability – a calculated mechanism underlying tumor progression. J Mol Med 2007, 85:139-148.
2. L. Ruiz A, Lloret M, Bordon E, Apolinario RM, Varona J, Millan AL, Alonso AR, Belka C: Hypoxia downregulates Ku70/80 expression in cervical carcinoma tumors. Radiat Oncol 2008, 8:222-226.
3. Wood RD: DNA repair in eukaryotes. Annu Rev Biochem 1996, 65:135-167.
4. Bindra RS, Crosby ME, Glazer PM: Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 2007, 26:249-260.
5. Tatum JL, Kellof GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelmann WC, Fyles AW, Gavrieli AJ, Hill AR, Koch C, Krishna MC, Krohn KA, Lewis JS, Macionis RI, Mello G, Puthari AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffmann J, Liu G, Stone H, Sullivan D: Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82:699-757.
6. Hockel M, Schlegier K, Aral B, Mitze M, Schaffer U, Vaupel P, Expression of Ku70 correlates with survival in carcinoma patients treated by radiochemotherapy. Int J Cancer 2007, 120:268-277.
7. Letang-Rebel I, Brisson C, Fabre M, Bergerat JP, Rebel G: Effect of pO2 on tumor antibiotic drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line. Anticancer Res 2008, 28:55-68.
8. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman AW, Levin W, Manchul L, Keane TJ, Hill RP: Oxygen predictions radiate response and survival in patients with cervical cancer. Radiat Oncol 1998, 48:149-156.
9. Sabase E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T: The involvement of hypoxia-inducible factor-α in the susceptibility to gamma-rays and chemotherapy drugs of oral squamous cell carcinoma cells. Int J Cancer 2007, 120:268-277.
10. Lloret M, Lara PC, Bordon E, Apolinario RM, Bordon E, Rey A, Falcon O, Alonso AR, Belka C: Hypoxia downregulates Ku70/80 expression in cervical carcinoma tumors. Radiat Oncol 2008, 8:222-226.
11. Lloret M, Lara PC, Bordon E, Apolinario RM, Bordon E, Rey A, Falcon O, Alonso AR, Belka C: Hypoxia downregulates Ku70/80 expression in cervical carcinoma tumors. Radiat Oncol 2008, 8:222-226.
12. Clavo A, Raval-Fernandes S, Stephan AG, LaFemina MJ, Schepker RJ, Kickhoefer VA, Rome LH: Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 2001, 92:195-202.
13. Langer C, Walther W, Schwab H, Stein U: Cloning and initial analysis of the human multidrug resistance–related MVP/LRP gene promoter. Biochem Biophys Res Commun 2000, 278:125-133.
14. Stein U, Wolter W, Laurencoet CM, Scheffer GL, Schepker RJ, Shoemaker RH: Tumor necrosis factor-alpha and expression of the multidrug resistance–associated genes LRP and MRP. J Natl Cancer Inst 1997, 89:807-813.
15. Mossink MH, van Zon A, Schepker RJ, Sonneveld P, Wiemer EA: Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 2003, 22:7458-7467.
16. Supranolet MC, Schepker RJ, Shoemaker RH, Mallord: Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP. Cytotechnology 1998, 27:137-148.
17. Silva P, West CM, Huang LE, Bindra RS, Glazer PM, Harris AL: Expression of Ku70 correlates with survival in carcinoma patients treated by radiochemotherapy. Int J Cancer 2007, 120:268-277.
18. Hill RP: Oxygen predictions radiate response and survival in patients with cervical cancer. Radiat Oncol 1998, 48:149-156.
19. Sabase E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T: The involvement of hypoxia-inducible factor-α in the susceptibility to gamma-rays and chemotherapy drugs of oral squamous cell carcinoma cells. Int J Cancer 2007, 120:268-277.
20. Clavo A, Raval-Fernandes S, Stephan AG, LaFemina MJ, Schepker RJ, Kickhoefer VA, Rome LH: Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 2001, 92:195-202.